Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Finnish Cancer Centre-Mid Finland, Tampere University Hospital, Tampere, Finland.
J Infect Dis. 2022 Sep 28;226(7):1195-1199. doi: 10.1093/infdis/jiac190.
For head-to-head comparison of human papillomavirus (HPV) antibody levels induced by different vaccines, 25-year-old vaccine-naive women were given either the bivalent (n = 188) or the nonavalent HPV vaccine (n = 184). Six months after vaccination antibodies against pseudovirions from 17 different HPV types (HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68/73) were measured. Antibodies against HPV16/18 were higher after bivalent HPV vaccination (mean international units [IU] 1140.1 and 170.5 for HPV16 and 18, respectively) than after nonavalent vaccination (265.1 and 22.3 IUs, respectively). The bivalent vaccine commonly induced antibodies against the nonvaccine HPV types 31/33/35/45 or 58. The nonavalent vaccine induced higher antibodies against HPV6/11/31/33/45/52/58 and 35.
为了对头对头比较不同疫苗诱导的人乳头瘤病毒（HPV）抗体水平，25 岁的疫苗初免女性分别接种二价（n=188）或九价 HPV 疫苗（n=184）。接种后 6 个月，测量了针对来自 17 种不同 HPV 类型（HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68/73）的假病毒的抗体。二价 HPV 疫苗接种后，HPV16/18 抗体水平更高（HPV16 和 18 的国际单位[IU]分别为 1140.1 和 170.5），而非九价疫苗接种后（分别为 265.1 和 22.3 IU）。二价疫苗通常诱导针对非疫苗 HPV 类型 31/33/35/45 或 58 的抗体。九价疫苗诱导针对 HPV6/11/31/33/45/52/58 和 35 的抗体水平更高。
